Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Expected to Announce Quarterly Sales of $110.60 Million

Equities research analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) to report $110.60 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Amphastar Pharmaceuticals’ earnings. The highest sales estimate is $118.20 million and the lowest is $106.50 million. Amphastar Pharmaceuticals posted sales of $103.02 million in the same quarter last year, which suggests a positive year-over-year growth rate of 7.4%. The company is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Amphastar Pharmaceuticals will report full-year sales of $494.06 million for the current year, with estimates ranging from $472.84 million to $537.00 million. For the next financial year, analysts anticipate that the company will post sales of $546.94 million, with estimates ranging from $522.20 million to $584.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) last released its quarterly earnings results on Thursday, March 10th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.04. The business had revenue of $120.89 million for the quarter, compared to the consensus estimate of $111.38 million. Amphastar Pharmaceuticals had a net margin of 14.19% and a return on equity of 15.16%. During the same quarter last year, the firm earned $0.16 EPS.

A number of equities analysts have weighed in on the stock. Piper Sandler boosted their target price on shares of Amphastar Pharmaceuticals from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Friday, March 11th. Northland Securities upped their target price on shares of Amphastar Pharmaceuticals from $33.00 to $43.00 in a research note on Monday, April 11th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 19th. StockNews.com initiated coverage on shares of Amphastar Pharmaceuticals in a report on Thursday, March 31st. They issued a “buy” rating for the company. Finally, Wells Fargo & Company upped their price target on shares of Amphastar Pharmaceuticals from $23.00 to $32.00 and gave the company an “equal weight” rating in a report on Tuesday, March 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $33.50.

In other news, CFO William J. Peters sold 7,900 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 15th. The shares were sold at an average price of $34.46, for a total value of $272,234.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael A. Zasloff sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, March 16th. The shares were sold at an average price of $33.71, for a total transaction of $337,100.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 36,400 shares of company stock worth $1,110,244. 28.40% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Quadrant L P CA purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $36,000. Allworth Financial LP purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $42,000. Lazard Asset Management LLC bought a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at about $42,000. Advisor Group Holdings Inc. raised its stake in Amphastar Pharmaceuticals by 314.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 2,311 shares of the company’s stock valued at $54,000 after acquiring an additional 1,753 shares during the period. Finally, Royal Bank of Canada raised its stake in Amphastar Pharmaceuticals by 253.4% in the 2nd quarter. Royal Bank of Canada now owns 3,534 shares of the company’s stock valued at $71,000 after acquiring an additional 2,534 shares during the period. 59.69% of the stock is owned by institutional investors and hedge funds.

Shares of Amphastar Pharmaceuticals stock opened at $38.43 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.17 and a current ratio of 3.06. The company’s 50-day simple moving average is $33.02. Amphastar Pharmaceuticals has a twelve month low of $17.01 and a twelve month high of $44.46. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 30.99 and a beta of 0.69.

Amphastar Pharmaceuticals Company Profile (Get Rating)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Featured Articles